A5020195149- Alzheimer's disease research and treatments
- Epigenetics and DNA Methylation
- Dementia and Cognitive Impairment Research
- Mitochondrial Function and Pathology
- Metabolomics and Mass Spectrometry Studies
- Diet and metabolism studies
- Circular RNAs in diseases
- Bioinformatics and Genomic Networks
- Folate and B Vitamins Research
- MicroRNA in disease regulation
- ATP Synthase and ATPases Research
Geriatric Research Education and Clinical Center
2018-2023
VA Puget Sound Health Care System
2018-2023
University of Puget Sound
2023
University of Washington
2018
The apolipoprotein E gene (APOE) is the strongest genetic risk factor for late-onset Alzheimer's disease (AD), yet expression of APOE not clearly understood. For example, it unclear whether AD patients have elevated or decreased why correlation levels RNA and ApoE protein differ across studies. Likewise, has a single CpG island (CGI) that overlaps with its 3'-exon, this CGI's effect unknown. We previously reported CGI highly methylated in human postmortem brain (PMB) methylation altered...
Increasing evidence suggests that the Translocase of Outer Mitochondria Membrane 40 (TOMM40) gene may contribute to risk Alzheimer’s disease (AD). Currently, there is no consensus as whether TOMM40 expression up- or down-regulated in AD brains, hindering a clear interpretation TOMM40’s role this disease. The aim study was determine if RNA levels differ between and control brains. We applied RT-qPCR transcription human postmortem brain (PMB) assessed associations these with genetic variants...
The Apolipoprotein E (APOE) locus has garnered significant clinical interest because of its association with Alzheimer's disease (AD) and longevity. This genetic appears across multiple genes in the APOE locus. Despite apparent differences between AD longevity, both conditions share a commonality aging-related changes mitochondrial function. is likely due to accumulative biological effects partly exerted by In this study, we investigated structure/function-related markers using oxidative...
Pathological amyloid-β and α-synuclein are associated with a spectrum of related dementias, ranging from Alzheimer's disease (AD) dementia Lewy bodies (DLB) to Parkinson (PDD). While these diseases share clinical pathological features, they also have unique patterns pathology. However, epigenetic factors that contribute differences remain unknown. In this preliminary study, we explore in DNA methylation transcription five neuropathologically defined groups: cognitively unimpaired controls,...
Abstract Introduction Inheritance of the ε4 allele apolipoprotein E ( APOE ) increases a person's risk developing both Alzheimer's disease (AD) and Lewy body dementia (LBD), yet underlying mechanisms behind this are incompletely understood. The recent identification reduced DNA methylation in AD postmortem brains prompted study to investigate LBD. Methods Genomic from brain tissues (frontal lobe cerebellum) neuropathological pure (np) controls npAD, LBD + AD, npLBD subjects were bisulfite...
The APOE locus has garnered significant clinical interest because of its association with Alzheimer's disease (AD) and longevity. This genetic appears across multiple genes in the locus. Despite apparent differences between AD longevity, both conditions share a commonality aging-related changes mitochondrial function. is likely due to accumulative biological effects, partly exerted by In this study, we investigated structure/function-related markers using oxidative stress-induced...
The apolipoprotein E gene (APOE) is the strongest genetic risk factor for late-onset Alzheimer's disease (AD). Differential expression of APOE's RNA and protein have been observed in AD; however, APOE levels do not always correlate with ApoE levels. It remains controversial whether AD patients elevated or decreased expression. These observations suggest that APOE’s transcriptional regulation complex. Additionally, has a single CpG island (CGI) overlaps its 3’-exon, which harbors two...